HOME >> MEDICINE >> NEWS
'EuroVacc 02' HIV vaccine trial begins in February 2005

Lausanne, Switzerland and London, United Kingdom, February 16, 2005 -- The European Vaccine Effort against HIV/AIDS, today announced that a phase I clinical trial of novel investigational vaccines comprising DNA-HIV-C and NYVAC-HIV-C for the prevention of HIV infection has started in Lausanne and London in February 2005. These vaccines are based on HIV subtype C, which is prevalent in China, India and sub-Saharan Africa, and constitutes more than 50 percent of the new HIV infections worldwide.

The phase I clinical trial, with the EuroVacc Foundation as the sponsor, will evaluate the safety of DNA-HIV-C alone and of the prime-boost regimen of DNA-HIV-C+NYVAC-HIV-C, and to compare the immunogenicity of the prime-boost regimen to NYVAC-HIV-C alone in healthy volunteers at low risk of acquiring HIV infection. The study will recruit 40 healthy volunteers: 20 at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, and 20 at St Mary's Hospital, Imperial College London. All volunteers, male or female, should be between 18 and 55 yrs, HIV-negative and at low risk of infection.

The trial will carefully evaluate the safety and immunogenicity of the combination of the vaccines, in particular their ability to generate HIV-specific cell-mediated immune response to HIV, which is considered to be a key determinant of protection against infection. According to the principal clinical investigators Prof. Giuseppe Pantaleo of CHUV in Lausanne and Prof. Jonathan Weber of Imperial College London for the clinical studies, "if this study generates promising results, EuroVacc intends to further evaluate the vaccines in larger clinical trials."

Development background

The vaccine candidates for the trial - DNA-HIV-C and NYVAC-HIV-C - were developed within the network European Vaccine Effort against HIV/AIDS. NYVAC-HIV-C (a vaccine candidate based on poxvirus) was manufactured by sanofi pasteur - the vaccine division of Sanofi-Aventis - a
'"/>

Contact: Tony Stephenson
at.stephenson@imperial.ac.uk
44-207-594-6712
Imperial College London
16-Feb-2005


Page: 1 2

Related medicine news :

1. Pitt marks 50th anniversary of its Salk polio vaccine with reunion, scientific symposium
2. NIAID initiates trial of experimental avian flu vaccine
3. Study finds majority of women willing to accept cervical cancer vaccine for self and children
4. Invasive pneumonia and antibiotic resistance decreased after childhood vaccine introduced
5. Earlier use of prostate cancer vaccines urged by Hopkins scientists
6. Researchers close in on breast cancer vaccine
7. Varicella vaccine effective on chicken pox; Impact on herpes zoster unclear
8. Pathogen-mimicking vaccine as strategy for cancer therapy
9. HIV vaccine trial breaks ground for future research
10. First US kidney cancer vaccine trial underway at Columbia
11. NIAID begins enrolling volunteers for novel HIV vaccine study

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/17/2019)... ... July 17, 2019 , ... In order to achieve the mission, the ... could occur, from the accident scene, to the moment the teeth are replanted and ... for treatment. , They identified seven points, so called links in a chain, along ...
(Date:7/17/2019)... ... July 17, 2019 , ... Becker's Healthcare is ... hospitals. , The men and women included on this list lead organizations regularly ... EHR implementations as well as the construction of satellite clinics and strategic partnerships ...
(Date:7/17/2019)... ... 17, 2019 , ... Athena Software , a leading ... worldwide, has been awarded a California Multiple Award Schedules (CMAS) agreement by the ... and local government agencies in California by designating pre-approved suppliers from whom they ...
(Date:7/17/2019)... ... July 17, 2019 , ... A new study led by ... the American Medical Association (JAMA), shows for the first time that New York’s ... state. Sepsis is the body’s extreme response to infection. It kills more than 275,000 ...
(Date:7/17/2019)... ... , ... Women’s Excellence is pleased to announce a new office opening in Lapeer, Michigan. ... resides on the corner of Turrill Road and South Lapeer Roads, conveniently off of I-69 ... of our new office in Lapeer and the ability to service women in this community. ...
Breaking Medicine News(10 mins):
(Date:7/18/2019)... ... July 18, 2019 , ... Phlexglobal today announced ... regulatory guidelines and achieve optimum TMF Health. , United Kingdom Lunch and ... host two Lunch and Learn events to present information about the new EMA ...
(Date:7/17/2019)... FORT WASHINGTON, Pa. (PRWEB) , ... July 17, ... ... the new brand for its suite of CME subsidiaries: Global Learning Collaborative ... in our CME enterprise, including growth in subsidiaries, scientific teams, leadership, and educational ...
(Date:7/17/2019)... ... July 17, 2019 , ... Updox , a ... new customers, better engage existing patients and collaborate with prescribers, today announced it ... tandem with an all-in-one platform. With the Updox approach, pharmacies are backed by ...
Breaking Medicine Technology:
Cached News: